Heyuan Biotechnology (Shanghai) Co., Ltd
Initial public offering and listing on the science and Innovation Board
Announcement of issuance results
Sponsor (lead underwriter): Haitong Securities Company Limited(600837)
Co lead underwriter: Guotai Junan Securities Co.Ltd(601211)
hot tip
The application of Heyuan Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Heyuan biotechnology”, “issuer” or “company”) for the initial public offering of RMB common shares (A shares) (hereinafter referred to as “this offering”) has been examined and approved by the stock listing committee of the science and Innovation Board of Shanghai Stock Exchange, It has been approved to register by China Securities Regulatory Commission (hereinafter referred to as “CSRC”) (zjxk [2022] No. 61) Haitong Securities Company Limited(600837) (hereinafter referred to as ” Haitong Securities Company Limited(600837) ” or “sponsor (lead underwriter)”) serves as the sponsor (lead underwriter) of this offering, and Guotai Junan Securities Co.Ltd(601211) (hereinafter referred to as ” Guotai Junan Securities Co.Ltd(601211) “) serves as the joint lead underwriter of this offering ( Haitong Securities Company Limited(600837) and Guotai Junan Securities Co.Ltd(601211) collectively referred to as “joint lead underwriters”). The issuer’s stock is referred to as “Heyuan biology” for short, and the extension is referred to as “Heyuan biology” for short, with the stock code of 688238.
This issuance adopts directional placement to strategic investors (hereinafter referred to as “strategic placement”) Offline inquiry placement to qualified offline investors (hereinafter referred to as “offline issuance”) and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts market value in Shanghai market (hereinafter referred to as “online issuance”).
The issuer and the co lead underwriters comprehensively evaluated the reasonable investment value of the company, the secondary market valuation level of comparable companies and the secondary market valuation level of the industry, fully considered the effective subscription multiple of offline investors, market conditions, demand for raised funds, underwriting risk and other factors, and negotiated to determine the issue price of 13.23 yuan / share and the issue quantity of 100 million shares, All new shares are issued without transfer of old shares.
The initial strategic placement amount of this issuance is 30 million shares, accounting for 30% of this issuance. The subscription funds promised by the strategic investors have been fully remitted to the bank account designated by the sponsor (lead underwriter) within the specified time. The final number of strategic placements in this offering was 27315019 shares, accounting for 27.32% of the number of shares in this offering. The difference between the final strategic placement quantity and the initial strategic placement quantity of 268498100 shares has been transferred back to offline issuance.
Before the launch of the online and offline call back mechanism, the number of shares issued offline was 58684981 million, accounting for 80.74% of the number issued after deducting the final strategic placement; The number of shares issued online was 14 million, accounting for 19.26% of the number issued after deducting the final strategic placement.
According to the callback mechanism announced in the announcement of Heyuan Biotechnology (Shanghai) Co., Ltd. on initial public offering and listing on the science and Innovation Board (hereinafter referred to as the “issuance announcement”), since the initial effective subscription multiple of this online offering is 420063 times, more than 100 times, the issuer and the co lead underwriters decided to start the callback mechanism to deal with offline The scale of online issuance was adjusted, and 7.2685 million shares were transferred back from offline to online. After the callback mechanism was launched, the final number of shares issued offline was 51416481, accounting for 70.74% of the number issued after deducting the final strategic placement, and the final number of shares issued online was 21268500, accounting for 29.26% of the number issued after deducting the final strategic placement. After the callback mechanism was launched, the final winning rate of online issuance was 003616551%.
The online and offline subscription and payment work of this offering has been completed on March 15, 2022 (T + 2). 1、 Statistics of new share subscription
According to the data provided by Shanghai Stock Exchange and China Clearing Shanghai Branch, the joint lead underwriters have made statistics on the subscription of new shares issued online and offline. The results are as follows:
(I) strategic placement
In this offering, the selection of strategic investors is comprehensively determined after considering the qualification of investors and market conditions, mainly including the following categories:
(1) The employees of Fucheng Haifutong and yuanbiology participated in the collective asset management plan of the strategic placement of the science and Innovation Board (the senior management and core employees of the issuer participated in the special asset management plan established by the strategic placement); (2) Haitong innovation Securities Investment Co., Ltd. (related subsidiaries of the sponsor participating in the follow-up investment);
(3) Shanghai Guoxin Investment Development Co., Ltd. and Shanghai Zhangjiang Technology Venture Capital Co., Ltd. (large enterprises or their subordinate enterprises with strategic cooperation relationship or long-term cooperation vision with the issuer).
As of March 8, 2022 (T-3), all strategic investors have paid the subscription funds and the corresponding new share placement brokerage commission in full and on time (Haitong venture capital does not need to pay the new share placement brokerage commission). The amount of premium paid by the main underwriter before the initial allotment date (2023 + 17) will include the amount of premium paid by the main underwriter before the initial allotment date (2023 + 17).
The subscription results of strategic investors are as follows:
Number of shares allocated to sequential investors amount allocated to investors (yuan, the restricted issue number of new shares does not include Commission) Commission (yuan) (month)
Haitong innovation Securities Investment Co., Ltd
Division 140 Shenzhen Fountain Corporation(000005) 292000000 – 24
Fucheng Haifutong and yuanbiology employees
2 participate in the strategic placement collection of science and innovation board 97772661293532291864676615 12
Asset management plan
Shanghai Guoxin Investment Development Co., Ltd
Division 37520974995024860249751243 12
Shanghai Zhangjiang science and Technology Venture Capital Co., Ltd
4 limited company Henan Mingtai Al.Industrial Co.Ltd(601677) 9796019861739800993 12
Total 2731501936137770137154228851-
(II) online subscription of new shares
(1) Number of shares subscribed by investors online: 21096124
(2) Subscription amount paid by online investors (yuan): 27910172052
(3) Number of online investors giving up subscription (shares): 172376
(4) Subscription amount abandoned by online investors (yuan): 228053448
(III) offline subscription of new shares
(1) Number of shares subscribed by offline investors (shares): 51416481
(2) Subscription amount paid by offline investors (yuan): 68024004363
(3) Number of offline investors giving up subscription (shares): 0
(4) Subscription amount abandoned by offline investors (yuan): 0
(5) Brokerage commission for placement of new shares paid by offline investors (yuan): 340119826
2、 Offline placement lottery results
According to the announcement on IPO arrangement and preliminary inquiry of Heyuan Biotechnology (Shanghai) Co., Ltd. and the announcement on IPO of Heyuan Biotechnology (Shanghai) Co., Ltd. and listing on the science and innovation board, On the morning of March 16, 2022 (T + 3), the issuer and the co lead underwriters presided over the lottery winning ceremony of the online lower limit sales account of Heyuan biological initial public offering at the Haitang hall, the conference room on the fourth floor of Zijinshan Hotel, 778 Dongfang Road, Pudong, Shanghai.
The lottery ceremony was conducted in accordance with the principles of openness, fairness and impartiality. The process and results of the lottery have been notarized by Shanghai Oriental notary office. The winning results are as follows:
Last digit winning lot number
Last “1” digit 3
Last “4” digit 0587
Securities investment funds and other partial stock asset management products established by participating in offline issuance and subscription and public offering of A-share shares of Yuansheng biology, national social security fund, basic endowment insurance fund, enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund If the mantissa of the subscription allotment number held by the placement objects such as insurance funds and QFII funds that meet the relevant provisions of the measures for the administration of the use of insurance funds is the same as the above number, it is the winning number.
A total of 3071 accounts participated in the offline placement and lottery in this issuance, and the number of accounts corresponding to 10% of the final allocated accounts (rounded up) is 308. According to the lottery results, all the winning accounts have obtained the shares for this placement, and the sales restriction period is 6 months. The number of shares corresponding to this part of the account is 3676987 shares, accounting for 7.15% of the total offline issuance and 5.06% of the total public offering after deducting the number of strategic placement. Please refer to the “attached table: table of lottery results of offline placement” for the specific conditions of the placing objects who won the lottery in this offline lottery. 3、 Underwriting by the recommendation institution (lead underwriter)
The number of shares abandoned by online and offline investors is underwritten by the sponsor (lead underwriter). The number of shares underwritten by the sponsor (lead underwriter) is 172376 shares, and the underwriting amount is 228053448 yuan. The number of shares underwritten by the sponsor (lead underwriter) accounts for 0.17% of the total issued number.
On March 17, 2022 (T + 4), the recommendation institution (lead underwriter) transferred the remaining stock underwriting funds, the funds raised from strategic placement and the funds raised from offline and online issuance to the issuer together after deducting the recommendation underwriting fee and the brokerage commission for new share placement according to the recommendation underwriting agreement. The issuer submitted the application for share registration to China Clearing Shanghai Branch, Register the underwritten shares in the securities account designated by the sponsor (lead underwriter).
4、 Contact information of CO lead underwriters
If online and offline investors have any questions about the issuance results announced in this announcement, please contact the joint lead underwriter of this issuance.
The specific contact information is as follows:
1. Sponsor (lead underwriter): Haitong Securities Company Limited(600837)
Legal representative: Zhou Jie contact address: No. 689, Guangdong Road, Shanghai contact person: capital market department Tel.: 02123154759, 02123154758, 02123154756, 021231547572 joint lead underwriter: Guotai Junan Securities Co.Ltd(601211) legal representative: He Qing address: 37 / F, Bohua Plaza, No. 669, Xinzha Road, Jing’an District, Shanghai contact person: capital market department Tel.: 02138676888
Issuer: sponsor (lead underwriter) of Heyuan Biotechnology (Shanghai) Co., Ltd.: Haitong Securities Company Limited(600837) co lead underwriter: Guotai Junan Securities Co.Ltd(601211) March 17, 2022 (there is no text on this page, which is Heyuan Biotechnology (Shanghai)) (seal page of announcement on the results of initial public offering and listing on the science and Innovation Board of a joint stock limited company)
Issuer: Heyuan Biotechnology (Shanghai) Co., Ltd. (there is no text on this page, which is the seal page of the announcement on the results of Heyuan Biotechnology (Shanghai) Co., Ltd. initial public offering and listing on the science and Innovation Board)
Sponsor (lead underwriter): Haitong Securities Company Limited(600837) mm / DD / yyyy (there is no text on this page, which is the seal page of the announcement on the results of initial public offering and listing on the science and Innovation Board of Heyuan Biotechnology (Shanghai) Co., Ltd.)
Co lead underwriter: Guotai Junan Securities Co.Ltd(601211) mm / DD / yyyy
Attached table: lottery results of offline placement
